X

Trial Profile

An Adaptive Study of the Pharmacokinetics of Favipiravir in Patients With Severe Influenza

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Favipiravir (Primary) ; Oseltamivir
Indications Influenza virus infections
Focus Pharmacokinetics

Most Recent Events

11 Dec 2019 Results (N=168), comparing the effect of Favipiravir plus Oseltamivir combination therapy versus Oseltamivir monotherapy by using data from two trials ( NCT03394209 and NCT02492425) published in the Journal of Infectious Diseases.
14 May 2019 Status changed from active, no longer recruiting to completed.
10 Jan 2019 Planned End Date changed from 10 Feb 2019 to 10 Mar 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com